24KIT
Kit that's coming soon
A brief round-up about what could be coming our way
in the fairly near future. By Sue Marshall
Tandem Mobi
In an article for Medscape.com by Miriam E. Tucker dated
mid-July2023, it was reported that, "The US Food and
Drug Administration has cleared the Tandem Mobi insulin
pump for use by people with Type 1 diabetes aged 6 years
or older. The product is half the size of the company's
t:slim X2 and is now the smallest of the commercially
available, durable tubed pumps. It is fully controllable
from a mobile app through a user's compatible iPhone.
"Features of the Mobi include a 200-unit insulin
cartridge and an on-pump button that can be used
instead of the phone for bolusing insulin. The device can
be clipped to clothing or worn on-body with an adhesive
sleeve that is sold separately.
"The Mobi is compatible with all existing Tandembranded
infusion sets manufactured by the Convatec
Group, and there is a new 5-inch tubing option made just
for the Tandem Mobi.
"The Mobi is part of a hybrid-closed loop automated
delivery system, along with the current Control-IQ
technology and a compatible continuous glucose
monitor (CGM). The CGM sensor predicts glucose
values 30 minutes ahead and adjusts insulin delivery
every 5 minutes to prevent highs and lows. Users must
still manually bolus for meals. The system can deliver
automatic correction boluses for up to 1 hour to prevent
hyperglycaemia.
Limited release of the Tandem Mobi is expected in late
2023 [in the US], followed by full commercial availability
in early 2024."
To read the article, CLICK HERE.
Omnipod 5 & FSL2
At the American Diabetes Association (ADA) 83rd
Scientific Sessions held in San Diego USA in late June
2023, Insulet president and CEO Jim Hollingshead
commented, "Insulet's flagship product, Omnipod 5, is
having an incredible impact on people with diabetes,
including improved glycaemic outcomes and better
quality of life. We are thrilled with the opportunity
to present real-world evidence from the first year on
Omnipod 5 in the US, and further educate diabetes
clinicians on how they can improve care for their patients
using our tubeless automated insulin delivery technology."
The company said that it submitted its Omnipod 5 App
for iPhone to the FDA for clearance. The company aims
to provide smartphone control for iOS mobile technology
users. It also said it enhanced its app's user interface to
align with the iOS operating system. It also added a new
custom food feature for the iPhone app.
The company also reported progress toward its goal
of giving Omnipod 5 users a choice over the sensor that
accompanies their pump. Currently, Omnipod 5 works
in conjunction with the Dexcom G6 continuous glucose
monitor (CGM). Insulet said it expects to soon begin
enrollment for a clinical study integrating Omnipod 5
with the Abbott FreeStyle Libre 2 sensor. This study aims
to recruit up to 200 participants with Type 1 diabetes,
both in the adult and paediatric age groups and spanning
the UK, France and Belgium. Insulet said it hopes to
demonstrate superior efficacy with Omnipod 5 compared
to people taking multiple daily injections.
Vertiva delivery system
As reported in Drug Delivery Business in mid-June
2023 by Sean Whooley, the Vertiva on-body delivery
system was unveiled by the Stevanato Group, the latest
release of its patented on-body drug delivery system.
As reported, "the Italy-based Stevanato Group
designed Vertiva with the ability to switch between basal
and bolus injections. It has suitability for a wide range
of subcutaneous therapies. In March, Stevanato Group
announced plans to bring this on-body device to market
through a collaboration with Thermo Fisher Scientific.
The companies plan to offer the platform as an integrated
device and fill-and-finish solution.
"The company designed Vertiva with a single-use pod